Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 23, 2023 - Issue 6
Submit an article Journal homepage
175
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China

Zhiwei Zhenga Department of pharmacy, Cancer hospital of Shantou University Medical College, Shantou, ChinaView further author information
,
Ling Fanga Department of pharmacy, Cancer hospital of Shantou University Medical College, Shantou, ChinaView further author information
,
Hongfu Caib Department of pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, ChinaCorrespondence[email protected]
View further author information
&
Huide Zhua Department of pharmacy, Cancer hospital of Shantou University Medical College, Shantou, ChinaCorrespondence[email protected]
View further author information
Pages 683-690 | Received 10 Jan 2023, Accepted 17 Apr 2023, Published online: 24 Apr 2023

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Shuo Kang, Xiaohui Wang, Zhenhua Pan & Huanlong Liu. (2023) Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-8.
Read now
Zhiwei Zheng, Hongcai Chen, Hongfu Cai & Huide Zhu. First-line tislelizumab for advanced or metastatic esophageal squamous cell carcinoma:A cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research 0:0.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.